Work

AVB500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab compared to bevacizumab alone in uterine serous cancer mouse model

Year: 2020

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.06.162

Authors: M.D. Toboni, J.I. Tankou, M.M. Mullen, A. Oplt, H. Noia, P. Cannon, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell, K.C. Fuh

Institution: Washington University in St. Louis

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097952898

FWCI:

Cites:

Cited by:

Related to: 10